MarketCap
Facebook
X
TelegramQuartalsbericht 2023-Q1
hinzugefügt 15.05.2023
CTI BioPharma Corp. Anteile 2011-2026 | CTIC
Anteile Jährlich CTI BioPharma Corp.
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 115 M | 90.1 M | 71.1 M | 58 M | 56.1 M | 36.4 M | 27.9 M | 18.8 M | 14.9 M | 11.4 M | 5.81 M | 3.43 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 115 M | 3.43 M | 42.4 M |
Anteile Vierteljährlich CTI BioPharma Corp.
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 132 M | 131 M | 122 M | 109 M | 99.8 M | 99.8 M | 93.8 M | 92.3 M | 76.4 M | 75.9 M | 73.7 M | 73.7 M | 62.5 M | 58 M | 58 M | 58 M | 58 M | 58 M | 58 M | 57.9 M | 50.3 M | 43 M | 42.9 M | 31.7 M | 28 M | 28.2 M | 28 M | 28 M | 27.8 M | 28 M | 176 M | 175 M | 174 M | 177 M | 145 M | 144 M | 142 M | 146 M | 111 M | 108 K | 107 M | 110 M | 52.9 M | 42.5 M | 40.8 M | 40.6 M | 37 M | 165 M | 203 M |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 203 M | 108 K | 85.1 M |
Anteile anderer Aktien in der Pharmaeinzelhändler
| Name | Anteile | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
33.4 M | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
1.08 K | - | -10.17 % | $ 12.2 K |  USA |
 |
Autolus Therapeutics plc
AUTL
|
255 M | $ 1.37 | -8.67 % | $ 350 M |  Britain |
 |
Aeglea BioTherapeutics
AGLE
|
60.3 M | - | - | $ 1.01 B | USA |
 |
Adagene
ADAG
|
56.3 M | $ 1.65 | 6.11 % | $ 92.9 M |  China |
 |
Alterity Therapeutics Limited
ATHE
|
2.41 B | $ 3.43 | -2.69 % | $ 8.25 B |  Australia |
 |
Biogen
BIIB
|
146 M | $ 177.93 | -4.15 % | $ 25.9 B | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
134 M | $ 65.89 | -0.06 % | $ 8.81 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
219 M | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
118 M | - | -13.47 % | $ 169 M |  France |
 |
Akero Therapeutics
AKRO
|
67.1 M | - | - | $ 3.67 B | USA |
 |
AVROBIO
AVRO
|
44.3 M | - | 1083.1 % | $ 745 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.58 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
80.5 M | - | -18.52 % | $ 27.3 M | Britain |
 |
AstraZeneca PLC
AZN
|
1.42 B | $ 94.4 | 0.82 % | $ 96.9 B | Britain |
 |
BeiGene, Ltd.
BGNE
|
1.37 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bellicum Pharmaceuticals
BLCM
|
30.8 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
68.9 M | - | -7.31 % | $ 87 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
75 M | - | - | - |  Russia |
 |
Ascendis Pharma A/S
ASND
|
54.8 M | $ 214.55 | 2.77 % | $ 5 B |  Danmark |
 |
Codiak BioSciences
CDAK
|
21.8 M | - | -55.98 % | $ 2.15 M | USA |
 |
ARCA biopharma
ABIO
|
16.8 M | - | 1052.0 % | $ 415 M | USA |
 |
Bristol-Myers Squibb Company
BMY
|
2.03 B | $ 55.84 | 0.13 % | $ 113 B | USA |
 |
Cerevel Therapeutics Holdings
CERE
|
162 M | - | - | $ 7.29 B | USA |
 |
Acasti Pharma
ACST
|
12.1 M | - | 4.01 % | $ 150 M |  Canada |
 |
Caladrius Biosciences
CLBS
|
8.33 M | - | -16.75 % | $ 25.8 M | USA |
 |
BioLineRx Ltd.
BLRX
|
663 M | $ 2.86 | - | $ 908 M |  Israel |
 |
Clearside Biomedical
CLSD
|
61.8 M | - | - | $ 25.3 M | USA |
 |
Chimerix
CMRX
|
88.6 M | - | - | $ 756 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
1.21 B | - | -15.15 % | $ 60.3 M | Britain |
 |
BioNTech SE
BNTX
|
244 M | $ 106.88 | 4.6 % | $ 27.2 B | Germany |
 |
Can-Fite BioPharma Ltd.
CANF
|
2.18 B | $ 4.18 | -1.65 % | $ 9.1 B | Israel |
 |
AIkido Pharma
AIKI
|
6.18 M | - | 1.93 % | $ 17.4 M | USA |
 |
Catalyst Biosciences
CBIO
|
65.8 M | $ 11.09 | 1.0 % | $ 730 M | USA |
 |
Albireo Pharma
ALBO
|
19.2 M | - | -0.23 % | $ 916 M | USA |
 |
CureVac N.V.
CVAC
|
186 M | - | - | $ 867 M | Germany |
 |
Acer Therapeutics
ACER
|
15.8 M | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
33.4 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
5.01 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
15.4 M | - | - | $ 7.46 M | Israel |
 |
Coherus BioSciences
CHRS
|
94.2 M | $ 1.69 | 2.12 % | $ 159 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
810 K | - | -11.43 % | $ 502 K | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
48.4 M | $ 28.99 | -1.39 % | $ 1.4 B | USA |
 |
Celldex Therapeutics
CLDX
|
64.4 K | $ 25.71 | 0.16 % | $ 1.66 M | USA |
 |
Cellectis S.A.
CLLS
|
44.8 M | $ 4.24 | -0.47 % | $ 116 M | France |
 |
Acorda Therapeutics
ACOR
|
1.24 M | - | -24.86 % | $ 820 K | USA |
|
Applied Molecular Transport
AMTI
|
38.8 M | - | - | $ 10.1 M | USA |
 |
Brickell Biotech
BBI
|
5.39 M | - | -5.38 % | $ 6.06 M | USA |
 |
Burford Capital Limited
BUR
|
219 M | $ 9.57 | -0.78 % | $ 1.55 B | Britain |